Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells.
A novel family of titanium alkoxides with two stable pyridinemethoxide moieties bound to a titanium metal center were synthesized and tested for cytotoxic activity on a variety of cancer cell lines using colony formation assays. One compound, (OPy)(2)Ti(4AP)(2), where OPy is NC(5)H(5)CH(2)O(-), and 4AP is 4-aminophenoxide ((-)OC(6)H(5)(NH(2))-4), demonstrated increased cytotoxicity in breast, colon, and pancreatic cancer cell lines at 100 nanomolar levels with only short exposures. Further, (OPy)(2)Ti(4AP)(2) had activity in colon and pancreatic cancer cell lines that are usually resistant to chemotherapy. This demonstrates that these titanium compounds may have a role in anti-cancer therapy, similar to platinum-based compounds, and the (OPy)(2)Ti(4AP)(2) compound specifically deserves further investigation as an anti-cancer agent in chemo-resistant solid tumors.
Williamson
Elizabeth A
EA
Department of Internal Medicine, University of New Mexico Cancer Center, 1201 Camino de Salud, Albuquerque, NM 87131, USA.
Boyle
Timothy J
TJ
Raymond
Rebecca
R
Farrington
Jacqueline
J
Verschraegen
Claire
C
Shaheen
Montaser
M
Hromas
Robert
R
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology*; D056831:Coordination Complexes / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000473:pathology*; D013997:Time Factors; D014410:Tumor Stem Cell Assay
D000970:Antineoplastic Agents; D056831:Coordination Complexes
J Organomet Chem. 2009 Dec 15;694(26):4134-4139
20177431
PLoS One. 2010 Feb 15;5(2):e9201
20169162
Oncol Rep. 2000 Jan-Feb;7(1):193-5
10601617
Cancer Res. 2000 Nov 1;60(21):6039-44
11085525
Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25
12050023
Cancer Res. 1991 Jun 1;51(11):2943-8
2032232
Nat Rev Cancer. 2007 Aug;7(8):573-84
17625587
Clin Cancer Res. 1998 Nov;4(11):2701-8
9829732
J Clin Oncol. 1998 Aug;16(8):2761-9
9704729
Mini Rev Med Chem. 2004 Jan;4(1):49-60
14754443
Inorg Chem. 2007 Mar 5;46(5):1825-35
17319735
Anticancer Drugs. 2005 Nov;16(10):1091-8
16222151
Breast Cancer Res. 2008;10(2):R25
18366788
Pancreatology. 2009;9(3):267-72
19407481
Br J Cancer. 1998 Jun;77(12):2088-97
9649119
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18075-80
16332963
PLoS One. 2009;4(4):e5323
19390626
Dalton Trans. 2008 May 7;(17):2328-34
18414758
Inorg Chem. 2008 Nov 17;47(22):10708-17
18937448
J Inorg Biochem. 2010 Sep;104(9):1006-9
20569990
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72
20101258
Eur J Cancer. 1998 Sep;34(10):1522-34
9893623
Curr Med Chem. 2000 Dec;7(12):1289-303
11032972